EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia
Press Release EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia May 7, 2024 EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Pyridam Farma for Commercialization of BINOSTO® in Indonesia Freienbach, May 7th 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development […]
EffRx Pharmaceuticals Signs Exclusive Licensing and Distribution Agreement with Lupin for Commercialization of BINOSTO® in Vietnam & Philippines
![EffRx-Newsroom-PressRelease-20240206](https://www.effrx.com/wp-content/uploads/2024/02/EffRx-Newsroom-PressRelease-20240206.png)
Freienbach, February 6, 2024 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
EffRx Pharmaceuticals Signs Exclusive Licensing Agreement With Radius Health To Commercialize BINOSTO® In The United States
![EffRx-Newsroom-PressRelease-20230929](https://www.effrx.com/wp-content/uploads/2023/09/EffRx-Newsroom-PressRelease-20230929.png)
Freienbach, September 19th, 2023 – EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the development and commercialization of musculoskeletal and rare diseases medications, today announced
Abiogen Pharma Completes the Acquisition of EffRx
![EffRx-Newsroom-PressRelease-20230529](https://www.effrx.com/wp-content/uploads/2023/05/EffRx-Newsroom-PressRelease-20230529.png)
Press Release Abiogen Pharma Completes the Acquisition of EffRx May 29, 2023 Abiogen Pharma Completes the Acquisition of EffRx EffRx Pharmaceuticals SA joins forces with Abiogen Pharma S.p.A. Read PR: Abiogen & EffRx Press Release Contact Wolleraustrasse 41B, 8807 Freienbach, Switzerland +41 44 503 78 60 info@effrx.com SHARE THIS ARTICLE
EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland
![EffRx-Newsroom-PressRelease-20220720](https://www.effrx.com/wp-content/uploads/2022/07/EffRx-Newsroom-PressRelease-20220720.png)
Press Release EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland July 20, 2022 EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, […]
World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe
![EffRx-Newsroom-PressRelease-20220720 (2)](https://www.effrx.com/wp-content/uploads/2022/07/EffRx-Newsroom-PressRelease-20220720-2.png)
Press Release World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe July 20, 2022 World Orphan Drug Alliance – combining forces to reach patients with rare diseases across the globe World Orphan Drug Alliance (WODA) is a new global alliance of full-service regional distributors for orphan drugs. WODA covers […]
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland
![EffRx-Newsroom-PressRelease-20220426](https://www.effrx.com/wp-content/uploads/2022/04/EffRx-Newsroom-PressRelease-20220426.png)
Press Release EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland April 26, 2022 EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland FREIENBACH, Switzerland –-BUSINESS WIRE–- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in […]